This vaccine targets both the original strain of the virus, but also the BA.4 and BA.5 sub-variants of the Omicron variant, the majority in Europe.
The European Medicines Agency (EMA) announced on Monday that it has begun an ongoing review of the use for children aged five to eleven of Pfizer’s Covid vaccine specifically targeting the BA.4 and BA.5 subvariants. of Omicron. The “adapted” vaccine targets both the original strain of the coronavirus, and sub-variants BA.4 and BA.5 of the Omicron variant, represent the majority of cases on the European continent.
“The EMA has launched an ongoing review for the use of the Comirnaty Original/Omicron BA.4-5 adapted vaccine, in children aged five to eleven,” the European regulator tweeted.
BioNTech has also applied
During “rolling review”, the EMA then assesses data for an expected next application as it becomes available. This speeds up the process of evaluating authorization requests.
Pfizer and BioNTech announced last week that they had applied to US health authorities for approval for children aged five to eleven of a ten-microgram booster dose of their Covid vaccine specifically targeting Omicron subvariants, and indicated that a similar request would soon be sent to the EMA.
The European regulator last month approved this vaccine targeting the Omicron BA.4 and BA.5 subvariants, but this specific booster dose is for people aged twelve. This adapted vaccine is, according to the EMA, more effective than its original version in triggering an immune response against the BA.4 and BA.5 sub-variants, which are more benign but more easily transmitted.
European health authorities recommended in September that the elderly and at risk of a severe form of Covid-19 be on the front line for the administration of vaccines adapted to the Omicron variant.
Source: BFM TV